News
Eric Green, M.D., Ph.D., formerly the NHGRI director, has been awarded by Fierce Pharma as a Fierce 50 Innovation Honoree. The Fierce 50 is designed to honor the 50 most influential leaders and organizations shaping the future of biopharma, healthcare, and life sciences. The Fierce editorial team
A monoclonal antibody therapy discovery that arose from a 2005 research collaboration between scientists at the National Cancer Institute (NCI) and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) has again been designated for human compassionate therapeutic use – this
Each year NIH Technology Transfer releases a list of the top 20 royalty-on-sales grossing products of the year based upon license agreements to inventions made by the NIH intramural research program. The list is broken down into four categories: vaccines and therapeutics, diagnostics
A novel anti-cancer therapy to target the Proviral Integration of the Moloney murine leukemia virus (PIM) kinases is available for licensing and co-development. PIM kinases are overexpressed in many solid cancers, which is predictive of poor survival in multiple cancer types. NIH inventors have